XTL Biopharmaceuticals Ltd.

XTLB

$2.50

-6.02%

N/A-$0.16

Healthcare

Biotechnology

NASDAQ

Negociación activa

XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, ...

Métricas clave de XTLB

Instantánea

Último / TTM · 6 periodos

Capitalización

$5.67M

ROCE

664.6%

EV / EBITDA

-4.63x

+0.0% YoY

Rendimiento FCF

-18.1%

+87.0% YoY

Ciclo de conversión de efectivo

0.0d

Ratio corriente

0.40

Resumen rápido

TTM —

Current ratio below 1.0

Negative working capital

Métricas clave

Último / TTM · 6 periodos

Tendencia de valoración

Tendencia de valoración table

Metric	2021	2022	2023	2024	2025	TTM
Market CapTotal market value of all shares outstanding.	$3.68M	$1.65M	$1.38M	$3.42M	$975,914.867	$5.67M
Enterprise ValueCompany value including debt and cash adjustments.	$715,068.2	$-445,649.815	$-25,112.35	$3.18M	$1.17M	$5.86M
EV / SalesHow many dollars investors pay per dollar of sales.	0.00x	0.00x	0.00x	7.06x	0.00x	0.00x
EV / EBITDAValuation multiple versus operating earnings before non-cash charges.	-0.69x	0.51x	0.03x	-3.42x	-1.55x	-4.63x
Net Debt / EBITDALeverage ratio using net debt divided by EBITDA.	2.88	2.38	1.83	0.25	-0.26	-0.15

Retornos + indicador ROCE

ROCE más reciente

664.6%

Prev year 664.6%

Retornos + indicador ROCE table

Metric	2021	2022	2023	2024	2025	TTM
ROEProfit generated from shareholders' equity.	8.2%	-33.7%	-0.1%	-18.9%	2743.7%	-269.0%
ROAProfit generated from total assets.	6.6%	-32.2%	-0.1%	-12.0%	-4198.2%	-4198.2%
ROICReturn generated on invested operating capital.	-16.1%	-22.0%	-34.5%	-15.8%	296.1%	400.1%
ROCEOperating return on long-term capital used.	-16.1%	-22.0%	-34.5%	-34.2%	664.6%	664.6%
Earnings YieldEarnings as a percentage of market value.	11.8%	-81.8%	-0.1%	-30.1%	-714.1%	-129.8%

Calidad del flujo de caja

Calidad del flujo de caja table

Metric	2021	2022	2023	2024	2025	TTM
FCFFCash flow available to all capital providers.	$-1.03M	$-890,001	$-703,001	$-1.60M	$-1.02M	$-1.02M
FCFECash flow available to equity holders after debt flows.	$-1.05M	$-901,000	$-707,000	$-1.69M	$-817,000	$-817,000
FCF YieldFree cash flow divided by market capitalization.	-28.5%	-54.7%	-51.4%	-49.0%	-105.0%	-18.1%
Income QualityHow well accounting earnings are backed by cash flow.	-2.41	0.67	0.40	1.58	0.15	0.15
Capex / OCFShare of operating cash flow spent on capital expenditures.	0.0%	0.0%	0.0%	-3.3%	0.0%	0.0%

Eficiencia operativa

Eficiencia operativa table

Metric	2021	2022	2023	2024	2025	TTM
DSOAverage days to collect cash from customers.	0.0d	0.0d	0.0d	80.1d	0.0d	0.0d
DIOAverage days inventory stays before being sold.	0.0d	0.0d	0.0d	0.0d	0.0d	0.0d
DPOAverage days the company takes to pay suppliers.	730.0d	730.0d	0.0d	159.7d	0.0d	0.0d
Operating CycleTime from buying inventory to collecting receivables.	0.0d	0.0d	0.0d	80.1d	0.0d	0.0d
Cash Conversion CycleNet days cash is tied in operations.	-730.0d	-730.0d	0.0d	-79.6d	0.0d	0.0d

Instantánea

Último / TTM: —

Capitalización

$5.67M

ROE

-269.0%

Rendimiento FCF

-18.1%

Ratio corriente

0.40

Upstream

Yeda Research and Development Company Ltd. (Weizmann Institute of Science)Ligand Pharmaceuticals Incorporated (via CyDex Pharmaceuticals / Captisol)NASDAQ:LGNDBio-GAL (Biogal Galed Labs)Psyga Bio Ltd. (Being Acquired by XTL)Technion – Israel Institute of TechnologyUnlisted Peptide Synthesis CDMOs (Industry Structure)Unlisted CROs (Clinical Research Organizations)

Downstream

Biossil Inc.Weizmann Institute of Science / Yeda ResearchFuture Lupus / Sjögren's Syndrome Patient PopulationFuture Multiple Myeloma Patient Population

Empresas proxy

Ligand Pharmaceuticals IncorporatedNASDAQ:LGNDBiossil Inc.UnconfirmedYeda Research and Development Company Ltd.UnconfirmedWeizmann Institute of ScienceUnconfirmed

Sobre nosotrosPolítica de privacidadTérminos de servicioAviso legalDirectorio de accionesETFÍndicesCarteras 13FPrecios objetivoHerramientas gratuitasMapa tecnológicoÚnete a nuestro Slack

Plutux no es un asesor de inversiones. Los datos de mercado y el análisis generado por IA son solo informativos y educativos, no asesoramiento de inversión. Aviso legal

No se encontraron acciones que coincidan

XTL Biopharmaceuticals Ltd.

Métricas clave de XTLB

Métricas clave

Tendencia de valoración

Retornos + indicador ROCE

Calidad del flujo de caja

Eficiencia operativa

Instantánea

Cadena de suministro de XTLB

Upstream

Downstream

Empresas proxy

Métricas clave de XTLB

Métricas clave

Tendencia de valoración

Retornos + indicador ROCE

Calidad del flujo de caja

Eficiencia operativa

Instantánea

Cadena de suministro de XTLB

Upstream

Downstream

Empresas proxy